ICER’s ‘Unsupported Price Increase’ Report Due This Fall
Report by the Institute for Clinical and Economic Review will seek to inform the public policy debate on price increases for prescription drugs.
You may also be interested in...
Pamela Brandt joins health technology assessment group after stints at Aegerion, Astellas and Abbott Labs.
Getting seven top pharma leaders in the same room, required to answer tough questions on drug pricing, is rare. Members of the Senate Finance Committee got that opportunity recently, but there are some questions our Pink Sheet reporters think they missed.
In an interview with the Pink Sheet, Laura and John Arnold Foundation VP Health Care Mark Miller discusses the foundation’s ongoing drug pricing priorities.